ArticleGynecologic oncology reports2025
Molecular characterization of ovarian mesonephric-like adenocarcinoma: Insights from single-cell RNA sequencing and mitochondrial metabolism.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Ovarian mesonephric-like adenocarcinoma (MLA) is a rare malignancy with limited understanding of its molecular features and therapeutic vulnerabilities. Although similar to uterine MLA, its unique characteristics remain undefined. This study aimed to characterize ovarian MLA using single-cell RNA sequencing (scRNA-seq) and compare it with high-grade serous ovarian cancer (HGSOC). Methods: We analyzed the cellular and molecular heterogeneity of an ovarian MLA sample using scRNA-seq. Differential gene expression and pathway analyses were performed to identify unique molecular signatures and therapeutic targets. HGSOC scRNA-seq datasets were used for comparative analysis. Results: Ovarian MLA demonstrated reduced heterogeneity, with a predominance of epithelial cells compared to HGSOC. Transcriptomic profiling revealed an upregulation of mitochondrial metabolism and lipid biosynthesis genes, indicating a metabolic shift toward oxidative phosphorylation. Gene enrichment and protein-protein interaction analyses identified distinct pathways, including mitochondrial biogenesis and dynamics, suggesting mitochondrial reprogramming. Conclusions: This study provides the first scRNA-seq-based molecular characterization of ovarian MLA, differentiating it from HGSOC. Findings suggest potential therapeutic avenues, with a proposed combination therapy targeting MAP kinase and PI3K/AKT/mTOR pathways. Validation in larger cohorts is necessary for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.